Pharmaceuticals

Global Rare Disease Genome Editing Industry Trends and Market Forecast 2026–2030

February 18, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the rare disease genome editing market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Rare Disease Genome Editing Market?

The rare disease genome editing market size has seen rapid expansion in recent years. This market is expected to expand from $1.29 billion in 2025 to $1.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.8%. The historical growth of this market is attributable to key factors such as advancements in gene editing technologies, a rise in the identification of rare genetic mutations, increased funding for genomic research, the initial success observed in gene therapy trials, and burgeoning academic research initiatives.

The rare disease genome editing market is projected to experience substantial expansion in the coming years, reaching $2.88 billion by 2030, driven by a compound annual growth rate (CAGR) of 17.5%. This growth throughout the forecast period is primarily attributed to increased investment in curative rare disease therapies, the rising adoption of precision medicine strategies, the expansion of clinical genome editing trials, growing regulatory support for orphan drugs, and heightened collaboration between biotech companies and healthcare providers. Significant trends expected during this period include the wider acceptance of CRISPR-based therapeutics, a sharpened focus on gene editing for monogenic disorders, the increasing application of personalized genome editing techniques, the development of advanced editing platforms, and improved integration of genomic data analytics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp

What Drivers Are Supporting Technological Adoption In The Rare Disease Genome Editing Market?

The future expansion of the rare disease genome editing market is anticipated to be driven by the growing emphasis on precision medicine. This tailored healthcare method involves utilizing an individual’s genetic makeup, environmental factors, and lifestyle choices to deliver more precise and efficacious therapies. The heightened attention to precision medicine stems from progress in genomic sequencing and the identification of biomarkers, which facilitate accurate diagnoses and specific treatment strategies. The rare disease genome editing market plays a supportive role in precision medicine by allowing for the precise rectification of genetic mutations, thereby enhancing the personalization and efficacy of treatments. This approach contributes to healthcare advancement by tackling the underlying causes of rare conditions, leading to better patient outcomes and a decreased dependence on managing symptoms alone. As an illustration, in March 2024, Novotech, an Australia-based biotechnology company, reported that in 2023, 43% of the 217 FDA-approved oncology therapies qualified as precision oncology treatments, with 78 of these therapies incorporating DNA or NGS-detectable biomarkers. Consequently, the growing emphasis on precision medicine is serving as a catalyst for the expansion of the rare disease genome editing market.

Which Segments Are Contributing To The Growth Of The Rare Disease Genome Editing Market?

The rare disease genome editing market covered in this report is segmented –

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

Which Trends Are Shaping Activity Within The Rare Disease Genome Editing Market?

Major companies operating in the rare disease genome editing market are focusing on developing advanced therapeutic platforms, such as CRISPR-based gene editing systems, to enhance treatment precision, improve therapeutic outcomes, and address previously incurable genetic diseases. These CRISPR-based gene editing systems represent innovative technologies that enable precise modifications to the genome, allowing for the correction of genetic defects or the introduction of therapeutic genes into cells. For instance, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc., a US-based biotechnology research company, and received conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is indicated for patients aged 12 and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy works by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, which reduces or eliminates disease symptoms and offers a potential functional cure for these conditions.

Who Are The Top-Performing Companies In The Rare Disease Genome Editing Market In Recent Years?

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

Which Region Currently Holds The Largest Share Of The Rare Disease Genome Editing Market?

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Rare Disease Genome Editing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28313&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2026, By The Business Research Company

Genome Editing Or Genome Engineering Market Report 2026

https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report

Crispr Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795